A Phase i Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer

Keyphrases

• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Temsirolimus 100%
• Pemetrexed 100%
• Phase I Trial 100%
• Mammalian Target of Rapamycin Pathway 40%
• Neutropenia 20%
• Dose-limiting Toxicity 20%
• Phase I Study 20%
• Maximum Tolerated Dose 20%
• Lung Cancer 20%
• Non-small Cell Lung Cancer (NSCLC) 20%
• Thrombocytopenia 20%
• Stable Disease 20%
• Cancer Development 20%
• Leukopenia 20%
• Best Response 20%
• Objective Response 20%
• Pathway Activation 20%
• TSC1 mutation 20%
• STK11 Gene 20%
• Antifolate 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Temsirolimus 100%
• Pemetrexed 100%
• Mammalian Target of Rapamycin 40%
• Neutropenia 20%
• Maximum Tolerated Dose 20%
• Lung Cancer 20%
• Thrombocytopenia 20%
• Antiinfective Agent 20%
• Leukopenia 20%
• Folic Acid Antagonist 20%
• Diseases 20%